Retinyl palmitate is an ester of Retinol and is the major form of vitamin A found in the epidermis. Retinyl palmitate has been widely used in pharmaceutical and cosmetic formulations.

RET-IN-23c is a potent and selective RET kinase inhibitor with IC50 of 61.2 nM, shows no significant inhibitory effect against VEGFR-2 and KDR.

RET agonist BT13 is a novel small molecule GDNF receptor RET agonist, potently and selectively activates RET and its downstream intracellular signaling cascades in immortalized cells (EC50~20 uM).

Repinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.

Repaglinide is a KIR6 (KATP) channel blocker that binds with high affinity for SUR1 when co-expressed with KIR6.2(Kd = 0.42 nM).

Remodelin Fluor is a small molecule analog of Remodelin, demonstrates in vivo activitiy against NAT10, significantly enhances the healthspan in a Lmna G609G HGPS mouse model..

Relacatib (SB-462795, GSK-462795) is a potent and orally bioavailable small molecule cathepsin inhibitor with Ki of 41, 68 and 53 pM for cathepsin K, L and V, respectively.

REDX-05358 is a novel potent, highly selective, orally bioavailable pan RAF inhibitor with IC50 of 0.1, 0.68, 0.171, and 0.076 nM for ARAF, BRAF, BRAF (V600E), and CRAF, respectively.

RCM-1 (FOXM1 inhibitor RCM-1) is a nontoxic, small molecule that inhibits FOXM1 activity in vitro and in vivo, inhibits GFP-FOXM1 in U2OS cells with EC50 of 0.72 uM.

RBPI-4 is a selective small molecule inhibitor of poly(ADP-ribose) glycohydrolase (PARG) with IC50 of 3.0 uM, effectively inhibit PARG in cellular lysate..

RB-101 is an mixed enkephalinase inhibitor that inhibits Aminopeptidase N and Neutral Endopeptidase with IC50 of 11 nM and 2 nM, respectively.

Rasagiline Mesylate is an antiparkinsonian and a selective irreversible MAO-B inhibitor.

Ramatroban (BAY u3405) is a thromboxane A(2) (TxA(2)) antagonist marketed for allergic rhinitis.

RaloxifeneHcl(LY156758 Hcl) is a second generation selective estrogen receptor antagonist.

Radalbuvir (GS-9669) is a highly optimized thumb site II nonnucleoside inhibitor of HCV NS5B polymerase with binding affinity of 1.35 nM for genotype 1b.

rac Pterosin B is a potent and specific SIK3 signaling inhibitor that suppresses SIK3 downstream cascades by up-regulating the phosphorylation levels in the SIK3 C-terminal regulatory domain.

R-999636 is a small molecule inhibitor that effectively inhibits the β-catenin/Tcf4 interaction with Ki of 8.8 uM in FP assay.

R-360163 is a small molecule inhibitor that effectively inhibits the β-catenin/Tcf4 interaction with Ki of 16 uM in FP assay.

R191 (R-191) is a potent, small molecule IRAK1/4 kinase inhibitor (IRAK4 IC50=3 nM), exhibits good selectivity against a broad panel of kinases.

Quinine HCl dihydrate

Quetiapine Sulfoxide is a metabolite of Quetiapine. Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and along with an antidepressant to treat major depressive disorder.

Quercetin dihydrate (Sophoretin)

QTX125 (QTX-125) is a novel potent, selective HDAC6 inhibitor, displays excellent selectivity over other HDACs.

QO IIR is a reversible, tight-binding inhibitor inhibitor of catechol-O-methyltransferase (COMT) with IC50 of 320 nM.

QM385 is a highly potent small molecule SPR inhibitor,that inhibits the BH4 pathway, blocking T cell proliferation and autoimmunity.

QM31 (SVT016426, Apaf-1 inhibitor QM31) is a cytoprotective agent that inhibits the formation of the apoptosome (IC50=7.9 uM in vitro), the caspase activation complex composed by Apaf-1, cytochrome c, dATP and caspase-9.

QL-X-138 is a selective and potent BTK/MNK dual kinase inhibitor with IC50 of 8, 107.4, and 26 nM for BTK, MNK1, and MNK2, respectively.

QL-IX-55 is a selective ATP-competitive inhibitor of mTORC1/2 with IC50s of 50/50/10-50 nM for Human mTORC1/Yeast mTORC1/Yeast mTORC2, respectively

QD325 is a potent redox modulator that induces Nrf2-mediated oxidative stress and unfolded protein responses in PDAC cells (IC50=0.9 uM).

QD 232 is a novel quinazolinedione-based redox modulator that potently inhibits Src/FAK and STAT3 phosphorylation, decreasing pancreatic cancer cell viability and migration.